PTC Therapeutics announced its first quarter 2025 financial results on May 6, 2025, reporting a substantial increase in total revenues to $1.18 billion, up from $210.1 million in Q1 2024. This significant increase was primarily driven by $986.2 million in collaboration and license revenue, largely attributable to the Novartis agreement.
The company reported a net income attributable to common stockholders of $866.6 million, or $10.04 per diluted share, a notable shift from a net loss of $91.6 million in Q1 2024. Net product revenue for the quarter was $153.4 million, a decrease from $177.6 million in Q1 2024, while royalty revenue increased to $36.4 million from $31.2 million.
As of March 31, 2025, PTC Therapeutics maintained a strong cash position with cash, cash equivalents, and marketable securities totaling over $2.0 billion. The company also narrowed its full-year 2025 total revenue guidance, reflecting confidence in its financial outlook and strategic initiatives.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.